Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04231747
Title	A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Juno Therapeutics, a Subsidiary of Celgene
Indications	diffuse large B-cell lymphoma follicular lymphoma marginal zone lymphoma B-cell lymphoma primary mediastinal B-cell lymphoma
Therapies	CC-97540
Age Groups:	adult \| senior
Covered Countries	USA \| CAN

Facility	City	State	Zip	Country	Details
Local Institution - 003	Birmingham	Alabama	35294-3300	United States	Details
Local Institution - 004	Atlanta	Georgia	30342	United States	Details
Local Institution - 011	Boston	Massachusetts	02114	United States	Details
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	United States	Details
Nebraska Medicine Fred and Pamela Buffett Cancer Center	Omaha	Nebraska	68105	United States	Details
Hackensack University Medical Center	Hackensack	New Jersey	07601	United States	Details
Local Institution - 001	New York	New York	10021	United States	Details
Local Institution - 008	New York	New York	10065	United States	Details
Local Institution - 010	Charlotte	North Carolina	28204	United States	Details
Oregon Health and Science University OHSU	Portland	Oregon	97239	United States	Details
Huntsman Cancer Institute - University of Utah	Salt Lake City	Utah	84112	United States	Details
Foothills Medical Centre - Tom Baker Cancer Centre	Calgary	Alberta	T2N 2T9	Canada	Details
Vancouver General Hospital	Vancouver	British Columbia	V5Z 1M9	Canada	Details
Juravinski Cancer Centre	Hamilton	Ontario	L8V 1C3	Canada	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field